Publicacions en col·laboració amb investigadors/es de National and Kapodistrian University of Athens (35)

2024

  1. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 12, Núm. 10, pp. 2648-2668.e2

  2. Workflow to facilitate the detection of new psychoactive substances and drugs of abuse in influent urban wastewater

    Journal of Hazardous Materials, Vol. 469

2023

  1. Comprehensive profiling and semi-quantification of exogenous chemicals in human urine using HRMS-based strategies

    Analytical and Bioanalytical Chemistry, Vol. 415, Núm. 29-30, pp. 7297-7313

  2. Festivals following the easing of COVID-19 restrictions: Prevalence of new psychoactive substances and illicit drugs

    Environment International, Vol. 178

  3. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 5, pp. 1169-1203

  4. Three years of wastewater surveillance for new psychoactive substances from 16 countries

    Water Research X, Vol. 19

  5. Wastewater-Based Epidemiology for the Assessment of Human Exposure to Environmental Pollutants

    Elsevier, pp. 1-261

  6. Wastewater-based epidemiology as a surveillance tool to assess human consumption of psychotropic substances: Alcohol, nicotine and caffeine as case studies

    TrAC - Trends in Analytical Chemistry, Vol. 167

2021

  1. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 3, pp. 648-676

  2. EAACI Biologicals Guidelines—Recommendations for severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 1, pp. 14-44

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Management of anaphylaxis due to COVID-19 vaccines in the elderly

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 10, pp. 2952-2964

2020

  1. Anwendung von biologika bei allergischen und Typ-2-entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie

    Allergologie, Vol. 43, Núm. 7, pp. 255-271

  2. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 11, pp. 2764-2774

  3. Editorial: Artificial Intelligence in Chemistry

    Frontiers in Chemistry

  4. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1043-1057

  5. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1023-1042

  6. Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines—Recommendations on the use of biologicals in severe asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 75, Núm. 5, pp. 1058-1068

  7. Spatio-temporal assessment of illicit drug use at large scale: evidence from 7 years of international wastewater monitoring

    Addiction, Vol. 115, Núm. 1, pp. 109-120

2019

  1. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 74, Núm. 5, pp. 855-873